Triacylglycerol fatty acid composition in diet-induced weight loss in subjects with abnormal glucose metabolism--the GENOBIN study

Ursula Schwab, Tuulikki Seppänen-Laakso, Laxman Yetukuri, Jyrki Agren, Marjukka Kolehmainen, David E Laaksonen, Anna-Liisa Ruskeepää, Helena Gylling, Matti Uusitupa, Matej Oresic, GENOBIN Study Group, Ursula Schwab, Tuulikki Seppänen-Laakso, Laxman Yetukuri, Jyrki Agren, Marjukka Kolehmainen, David E Laaksonen, Anna-Liisa Ruskeepää, Helena Gylling, Matti Uusitupa, Matej Oresic, GENOBIN Study Group

Abstract

Background: The effect of weight loss on different plasma lipid subclasses at the molecular level is unknown. The aim of this study was to examine whether a diet-induced weight reduction result in changes in the extended plasma lipid profiles (lipidome) in subjects with features of metabolic syndrome in a 33-week intervention.

Methodology/principal findings: Plasma samples of 9 subjects in the weight reduction group and 10 subjects in the control group were analyzed using mass spectrometry based lipidomic and fatty acid analyses. Body weight decreased in the weight reduction group by 7.8+/-2.9% (p<0.01). Most of the serum triacylglycerols and phosphatidylcholines were reduced. The decrease in triacylglycerols affected predominantly the saturated short chain fatty acids. This decrease of saturated short chain fatty acid containing triacylglycerols correlated with the increase of insulin sensitivity. However, levels of several longer chain fatty acids, including arachidonic and docosahexanoic acid, were not affected by weight loss. Levels of other lipids known to be associated with obesity such as sphingolipids and lysophosphatidylcholines were not altered by weight reduction.

Conclusions/significance: Diet-induced weight loss caused significant changes in global lipid profiles in subjects with abnormal glucose metabolism. The observed changes may affect insulin sensitivity and glucose metabolism in these subjects.

Trial registration: ClinicalTrials.gov NCT00621205.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. CONSORT chart showing selection of…
Figure 1. CONSORT chart showing selection of subjects for lipidomic analysis.
Figure 2. Fold changes and t -test…
Figure 2. Fold changes and t-test p-values between mean concentrations in the weight reduction and control groups at (A) baseline and (B) after the intervention for the 309 peaks, among them180 identified lipid molecular species.
Also shown are fold changes between lipid levels after (33 weeks) vs. before (0 weeks) the intervention and corresponding paired t-test p-values for the (C) control group and (D) weight reduction group. The ‘volcano plot’ arranges lipids along dimensions of biological and statistical significance. The first (horizontal) dimension is the fold change between the two groups (on a log scale, so that up and down regulation appear symmetric), and the second (vertical) axis represents the p-value for a t-test of differences within the group after and before the intervention. The line above which False Discovery Rate q-value <0.05 is marked. No lipid passed the q<0.05 treshold in panels A and C.
Figure 3. Box plots for four selected…
Figure 3. Box plots for four selected triacylglycerol (TG) lipids in the weight reduction group before (WR0) and after (WR33) intervention, as well as for the control group before (Ctr0) and after (Ctr33) intervention.
The fatty acid composition of the individual acyls of the respective TG particles are shown in parentheses.
Figure 4. Box plots for selected phospho-…
Figure 4. Box plots for selected phospho- and sphingolipids in the weight reduction (WR) and control (Ctr) groups at the beginning (WR0, Ctr0) and at the end (WR33, Ctr33) of the study.
GPCho, phosphatidylcholine; SM, sphingomyelin; Cer, ceramide.
Figure 5. Spearman rank correlation between the…
Figure 5. Spearman rank correlation between the fold change of triacylglycerol molecular species after and before the intervention in weight reduction group, and the corresponding (A) total TG fatty acid carbon chain length and (B) degree of TG fatty acid unsaturation.
(C) Changes in esterified fatty acid composition in weight reduction and control groups, as obtained by gas chromatography based fatty acid measurement. p-values were calculated using paired samples t-test (*p<0.05, **p<0.01).
Figure 6. Change in insulin sensitivity index…
Figure 6. Change in insulin sensitivity index SI (33 weeks vs. 0 weeks) vs. log-change of triacylglycerol TG(16:0/14:0/14:1) concentration.
The Spearman rank correlation was used to calculate correlation coefficient r. The regression line is based on linear regression.

References

    1. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med. 2005;56:45–62.
    1. Yu-Poth S, Zhao G, T E, Naglak M, Jonnalagadda S, et al. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 1999;69:632–646.
    1. Stefanick ML, Mackey S, Sheehan M, Ellswotrh N, Haskell WL, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998;339:12–20.
    1. Metz JA, Stern JS, Kris-Etherton P, Reusser ME, Morris CD, et al. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med. 2000;160:2150–2158.
    1. Lelliott C, Vidal-Puig AJ. Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes relat Metab Disord. 2005;28(Suppl. 4):S22–S28.
    1. Unger R. Lipotoxic diseases. Annu Rev Med. 2002;53:319–336.
    1. Medina-Gomez G, Gray S, Yetukuri L, Shimomura K, Campbell M, et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 2007;3:e64.
    1. Storlien LH, Baur LA, Kriketos AD, Pan DA, Cooney GJ, et al. Dietary fats and insulin action. Diabetologija. 1996;39:621–631.
    1. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol. 2003;14:15–19.
    1. Laaksonen DE, Lakka TA, Lakka H-M, Nyyssonen K, Rissanen T, et al. Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabet Med. 2002;19:456–464.
    1. Warensjö E, Riserus U, Vessby B. Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia. 2005;48:1999–2005.
    1. Vessby B, Aro A, Skarfors E, Berglund L, Salminen I, et al. The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes. 1994;43:1353–1357.
    1. Laitinen JH, Ahola IE, Sarkkinen ES, Winberg RL, Harmaakorpi-Iivonen PA, et al. Impact of intensified dietary therapy on energy and nutrient intakes and fatty acid composition of serum lipids in patients with recently diagnosed non-insulin-dependent diabetes mellitus. J Am Diet Assoc. 1993;93:276–283.
    1. Nelson JC, Jiang X-C, Tabas I, Tall A, Shea S. Plasma sphingomyelin and subclinical atherosclerosis: Findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2006;163:903–912.
    1. Samad F, Hester KD, Yang G, Hannun YA, Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes. 2006;55:2579–2587.
    1. Mehta D. Lysophosphatidylcholine: an enigmatic lysolipid. Am J Physiol Lung Cell Mol Physiol. 2005;289:L174–175.
    1. Rabini R, Galassi R, Fumelli P, Dousset N, Solera M, et al. Reduced Na(+)-K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes. 1994;43:915–919.
    1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241.
    1. Pietiläinen KH, Sysi-Aho M, Rissanen A, Seppänen-Laakso T, Yki-Järvinen H, et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects - a monozygotic twin study. PLoS ONE. 2007;2:e218.
    1. Watson AD. Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006;47:2101–2111.
    1. Yetukuri L, Katajamaa M, Medina-Gomez G, Seppänen-Laakso T, Puig AV, et al. Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol. 2007;1:e12.
    1. Ekroos K, Chernushevich IV, Simons K, Shevchenko A. Quantitative profiling of phospholipids by multiple precursor ion scanning on a hybrid quadrupole time-of-flight mass spectrometer. Anal Chem. 2002;74:941–949.
    1. Han X, Gross RW. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J Lipid Res. 2003;44:1071–1079.
    1. Schwudke D, Oegema J, Burton L, Entchev E, Hannich JT, et al. Lipid profiling by multiple precursor and neutral loss scanning driven by the data-dependent acquisition. Anal Chem. 2006;78:585–595.
    1. McAnoy AM, Wu CC, Murphy RC. Direct qualitative analysis of triacylglycerols by electrospray mass spectrometry using a linear ion trap. J Am Soc Mass Spectrom. 2005;16:1498–1509.
    1. Hermansson M, Uphoff A, Kakela R, Somerharju P. Automated quantitative analysis of complex lipidomes by liquid chromatography/mass spectrometry. Anal Chem. 2005;77:2166–2175.
    1. Houjou T, Yamatani K, Imagawa M, Shimizu T, Taguchi R. A shotgun tandem mass spectrometric analysis of phospholipids with normal-phase and/or reverse-phase liquid chromatography/electrospray ionization mass spectrometry. Rapid Comm Mass Spectrom. 2005;19:654–666.
    1. Kolehmainen M, Salopuro T, Schwab US, Kekalainen J, Kallio P, et al. Weight reduction modulates expression of genes involved in extracellular matrix and cell death: the GENOBIN study. Int J Obes. 2007 doi: 10.1038/sj.ijo.0803718.
    1. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2486–2497.
    1. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, et al. AHA Dietary Guidelines : Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000;102:2284–2299.
    1. Sarkkinen E, Schwab U, Niskanen L, Hannuksela M, Savolainen M, et al. The effects of monounsaturated-fat enriched diet and polyunsaturated-fat enriched diet on lipid and glucose metabolism in subjects with impaired glucose tolerance. Eur J Clin Nutr. 1996;50:592–598.
    1. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, et al. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther. 2003;5:1003–1015.
    1. Seppänen-Laakso T, Laakso I, Hiltunen R. Analysis of fatty acids by gas chromatography, and its relevance to research on health and nutrition. Anal Chim Acta. 2002;465:39–62.
    1. Laaksonen R, Katajamaa M, Päivä H, Sysi-Aho M, Saarinen L, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin induced changes in muscle. PLoS ONE. 2006;1:e97.
    1. Medina-Gomez G, Virtue S, Lelliott C, Boiani R, Campbell M, et al. The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific Peroxisome Proliferator-Activated Receptor-{gamma}2 isoform. Diabetes. 2005;54:1706–1716.
    1. Katajamaa M, Miettinen J, Oresic M. MZmine: toolbox for processing and visualization of mass spectrometry based molecular profile data. Bioinformatics. 2006;22:634–636.
    1. Storey JD. A direct approach to false discovery rates. J R Stat Soc B. 2002;64:479–498.
    1. Willett WC. New York, NY, USA: Oxford University Press; 1998. Nutritional epidemiology.
    1. Tremblay AJ, Despres J-P, Piche M-E, Nadeau A, Bergeron J, et al. Associations between the fatty acid content of triglyceride, visceral adipose tissue accumulation, and components of the insulin resistance syndrome. Metabolism. 2004;53:310–317.
    1. Vessby B, Tengblad S, Lithell H. Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. Diabetologia. 1994;37:1044–1050.
    1. Summers LKM, Fielding BA, Bradshaw HA, Ilic V, Beysen C, et al. Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. Diabetologia. 2002;45:369–377.
    1. Vessby B, Uusitupa M, Hermansen K, Riccardi G, Rivellese AA, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU study. Diabetologia. 2001;44:312–319.
    1. Shimabukuro M, Zhou Y, Levi M, Unger R. Fatty acid induced beta-cell apoptosis: a link between diabetes and obesity. Proc Natl Acad Sci USA. 1998;95:2498–2502.
    1. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab. 2006;291:E275–281.
    1. Sweeney G, Nazir D, Clarke C, Goettsche G. Ethanolamine and choline phospholipids in nascent very-low-density lipoprotein particles. Clin Invest Med. 1996;19:243–250.
    1. Ågren JJ, Hallikainen M, Vidgren H, Miettinen TA, Gylling H. Postprandial lipemic response and lipoprotein composition in subjects with low or high cholesterol absorption efficiency. Clin Chim Acta. 2006;366:309–315.
    1. Yang LV, Radu CG, Wang L, Riedinger M, Witte ON. Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood. 2005;105:1127–1134.
    1. Shalina S, Ousman SD. Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia. 2000;30:92–104.
    1. Glass CK, Witzum JL. Atherosclerosis: The road ahead. Cell. 2001;104:503–516.
    1. Murugesan G, Fox PL. Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized Low Density Lipoprotein. J Clin Invest. 1996;97:2736–2744.
    1. Schmidt K, Klatt P, Graier WF, Kostner GM, Kukovetz WR. High-density lipoprotein antagonizes the inhibitory effects of oxidized low-density lipoprotein and lysolecithin on soluble guanylyl cyclase. Biochem Biophys Res Comm. 1992;182:302–308.
    1. Matsuda Y, Hirata K, Inoue N, Suematsu M, Kawashima S, et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res. 1993;72:1103–1109.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する